Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. - Wikidata - awgldk - TriplyDB

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

http://www.wikidata.org/entity/Q33166175

about

Telomere and Telomerase Therapeutics in Cancer Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Implications of telomeres and telomerase in endometrial pathology Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Role of Telomeres and Telomerase in Aging and Cancer.Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Targeting telomerase with radiolabeled inhibitors.Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Telomere-driven diseases and telomere-targeting therapies.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Telomeres and telomerase in prostate cancer development and therapy.Developing Cures: Targeting Ontogenesis in Cancer.Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.Telomere Transcripts Target Telomerase in Human Cancer Cells.Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Modulation of telomere protection by the PI3K/AKT pathway.Structural Basis for Shelterin Bridge Assembly.Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells.Biological and clinical implications of telomere dysfunction in myeloid malignancies.Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Telomerase enzyme deficiency promotes metabolic dysfunction in murine hepatocytes upon dietary stress.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction.Modulation of Telomerase Activity in Cancer Cells by Dietary Compounds: A Review.Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells AAV9-mediated telomerase activation does not accelerate tumorigenesis in the context of oncogenic K-Ras-induced lung cancer

P2860

Q26744808-4BA07450-C42B-4B1E-98BF-6483B45C64DC Q26766319-AE85D4EA-0DD5-42DB-B3DB-C2083B47DFD0 Q28066490-FA4B1BE9-981D-4E80-87B2-F9610CFF6606 Q28076096-8EA8D4E4-0E0B-42CB-AEF1-5D506009DB9F Q33433450-6CB9F2F0-BFDE-4F8F-AAC2-73AEA5140240 Q33439918-4D0F23B1-A5F7-45AD-8BF6-DF54856D41BD Q33595912-076B9F6C-22BB-4BCF-925C-4C25AA3F63D7 Q36782943-1FBCB75C-AE59-4C21-A7D4-2132498614D4 Q36971261-023DEC05-86A4-405B-9998-754A48B034D4 Q37706670-2451D5A4-56AB-4B56-A405-C21A9772DC6D Q38594107-A5DE5586-FC93-4FE5-A4E5-F217C396B22D Q38613880-3557FE22-604B-452A-BE4A-B44A5476BFD5 Q38646051-3C7E9917-96BC-4C7D-BE94-ED3E06A8435E Q38672646-357A7730-B755-4F11-93FB-6CE9003D59E9 Q38744397-B418C77B-17A1-42EE-9C14-93C213EE9A30 Q38890930-076E979E-8B74-44B5-82B3-2C4067CC4E2E Q38924189-7F4FB453-ADCD-41FE-9AC7-47BC8DA24641 Q39158816-11A8E620-1CD5-4DBC-A079-D7127C3B803F Q39306368-9CC305F3-7EBC-4216-89DA-B1AF13A88FED Q39413214-FE46FFDE-5891-45E8-9F80-C4D4450A37C9 Q39441380-340DE1A2-5D03-4C86-9615-D4D1DE04969F Q39563439-380BC5F0-273E-401D-B641-EBED70C11722 Q40188503-E9BB6563-21A3-4C6F-8415-E1126471B1F6 Q40571128-E2E6C4EB-EDCD-4484-AFBF-5DFFC0120900 Q40603254-1CDE3C97-5F05-4369-B54F-CE9149B9B94D Q42062133-37B49F9E-6AD2-4DE1-944A-E33D4E0593F9 Q45329468-E529DECB-D3AF-406B-B847-3526A568FD9C Q46283027-4FB1FBF5-6F59-498A-B267-61DAFF908B24 Q46306025-95FBA309-E42D-4B44-80FC-CEF17429BFC6 Q46980175-47C6F95C-27DD-49BE-931A-905F5DAA62D3 Q47612537-5B1E1291-1DAD-4956-8A22-3D8A7C1CA8FB Q47784889-15453744-B003-4A1E-B74E-20E560C0E2F2 Q48351718-218A2AD0-6E9A-4E9E-9656-BA324858B059 Q48569299-74F35332-DD3E-45C3-9AA6-CCB4CE30EDA9 Q49565626-BF66EF84-105A-412C-8199-6353B26B8C90 Q50075192-41C0D958-06AD-42B6-8B8A-3F7980669623 Q50131963-8CC4679A-97D5-4B8A-9E78-E706C7B61D92 Q58579018-FA948375-5C89-4246-A80A-E0F8756001A9 Q58705137-2EDC453A-05ED-4464-B9B1-41ECAB3B4418 Q58775287-B9E0816E-603F-49C6-A3F5-E127FB4AB71A

P2860

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

http://www.wikidata.org/entity/Q33166175

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@ast

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@en

type

label

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@ast

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@en

prefLabel

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@ast

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

@en

P1433

Q33166175-07B965B8-0E63-431F-A1F8-DD95CCF34EA4

P1476

Q33166175-196C215D-B553-4261-954B-BA124CEFBBEF

P2093

Q33166175-022B3D63-04B9-4447-B0F6-4AA047518D90

Q33166175-05B476C6-A2EF-45D9-8AEE-58FD5574B197

Q33166175-1CD4EAE8-A211-42EF-AAD9-173146AC0ED0

Q33166175-1FD94F21-CA58-4F7F-B82E-8C86EA970AA1

Q33166175-44BFFDD0-BF12-44AD-B1B8-3B1B6ACBF136

Q33166175-702DCC9D-9B8D-4248-9509-8063D75FEAE4

Q33166175-7EC47EA9-D27D-4836-84EE-4C2BD1301A4F

Q33166175-B1751B70-A5DE-4F36-9ED3-8733BCBDCFFD

Q33166175-C714A3A4-D4D4-4CB0-9350-D8B15A7F52B6

P304

Q33166175-8204A810-F4CB-4050-B476-1562716BC691

P31

Q33166175-D22EA840-67E2-4F7F-84AB-5A26EFDF7FC2

P356

Q33166175-D9AB503E-1509-4ADE-83FD-07D7D6BF283D

P407

Q33166175-4F5C89FA-9923-4445-9A24-05FBCF637782

P433

Q33166175-56B53E37-C8F7-435B-8FA0-4C7BE6B25729

P478

Q33166175-B4F194EE-1402-49F5-8831-E06B30505CA5

P50

Q33166175-6547E1F7-9329-4422-996C-77DA7C31E00A

Q33166175-D58D68E4-FEF5-41FD-B924-A05E677CE2AE

P577

Q33166175-CDCB6522-9653-427E-AFA5-4A54F07C0113

P698

Q33166175-008BBD7D-C434-427D-AF30-505FDCE6FD5D

P356

P1433

The New England Journal of Medicine

P1476

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

@en

P2093

Alexander Röth

http://www.w3.org/2001/XMLSchema#string

Bart Burington

http://www.w3.org/2001/XMLSchema#string

David S Snyder

http://www.w3.org/2001/XMLSchema#string

Elisabeth Oppliger Leibundgut

http://www.w3.org/2001/XMLSchema#string

Gabriela M Baerlocher

http://www.w3.org/2001/XMLSchema#string

Gary Spitzer

http://www.w3.org/2001/XMLSchema#string

Michael A McDevitt

http://www.w3.org/2001/XMLSchema#string

Monic Stuart

http://www.w3.org/2001/XMLSchema#string

Olatoyosi Odenike

http://www.w3.org/2001/XMLSchema#string

P304

920-928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1503479

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Michael Daskalakis

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26332546

http://www.w3.org/2001/XMLSchema#string